These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 12037733)

  • 1. Circulating soluble Fas ligand correlates with disease activity in Graves' hyperthyroidism.
    Wang CY; Zhong WB; Chang TC; Tsai YF
    Metabolism; 2002 Jun; 51(6):769-73. PubMed ID: 12037733
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating nuclear matrix protein in Graves' disease.
    Hara H; Morita Y; Sato R; Ban Y
    Endocr J; 2002 Jun; 49(3):343-7. PubMed ID: 12201219
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Increased serum soluble Fas ligand in hyperthyroid Graves' disease].
    Takeda K; Ohara E; Kaneda T; Hashimoto K; Sasaki M
    Rinsho Byori; 1999 Oct; 47(10):961-5. PubMed ID: 10590671
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Soluble Fas, Fas ligand and Bcl-2 in autoimmune thyroid diseases: relation to humoral immune response markers.
    Myśliwiec J; Okota M; Nikołajuk A; Górska M
    Adv Med Sci; 2006; 51():119-22. PubMed ID: 17357290
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma Fas ligand, an inducer of apoptosis, and plasma soluble Fas, an inhibitor of apoptosis, in advanced melanoma.
    Mouawad R; Khayat D; Soubrane C
    Melanoma Res; 2000 Oct; 10(5):461-7. PubMed ID: 11095407
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of levothyroxine treatment on serum levels of soluble Fas (CD95) and Fas Ligand (CD95L) in chronic autoimmune hypothyroidism.
    Nabipour I; Kalantarhormozi M; Assadi M; Jafari SM; Gharibi M; Ahmadi E; Sanjdideh Z
    Endocrine; 2010 Dec; 38(3):406-11. PubMed ID: 21042884
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum thyrotropin receptor antibodies concentrations in patients with Graves' disease before, at the end of methimazole treatment, and after drug withdrawal: evidence that the activity of thyrotropin receptor antibody and/or thyroid response modify during the observation period.
    Carella C; Mazziotti G; Sorvillo F; Piscopo M; Cioffi M; Pilla P; Nersita R; Iorio S; Amato G; Braverman LE; Roti E
    Thyroid; 2006 Mar; 16(3):295-302. PubMed ID: 16571093
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Decreased serum level of IL-7 in patients with active Graves' disease.
    Motylewska E; Nieć M; Siejka A; Komorowski J; Ławnicka H; Świętosławski J; Stępień H
    Cytokine; 2015 Oct; 75(2):373-9. PubMed ID: 26113403
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Examination of soluble Fas (sFas) and soluble Fas ligand (sFasL) in patients with burns.
    Yamada Y; Endo S; Nakae H; Makabe H; Sato N; Wakabayashi G; Kitamura M; Inada K; Sato S
    Burns; 2003 Dec; 29(8):799-802. PubMed ID: 14636754
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The association of TSH-receptor antibody with the clinical and laboratory parameters in patients with newly diagnosed Graves' hyperthyroidism: experience from a tertiary referral center including a large number of patients with TSH-receptor antibody-negative patients with Graves' hyperthyroidism.
    Zuhur SS; Bilen O; Aggul H; Topcu B; Celikkol A; Elbuken G
    Endokrynol Pol; 2021; 72(1):14-21. PubMed ID: 32944926
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Binding, stimulating and blocking TSH receptor antibodies to the thyrotropin receptor as predictors of relapse of Graves' disease after withdrawal of antithyroid treatment.
    Quadbeck B; Hoermann R; Hahn S; Roggenbuck U; Mann K; Janssen OE
    Horm Metab Res; 2005 Dec; 37(12):745-50. PubMed ID: 16372228
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum soluble Fas (CD95) and Fas ligand profiles in chronic kidney failure.
    Perianayagam MC; Murray SL; Balakrishnan VS; Guo D; King AJ; Pereira BJ; Jaber BL
    J Lab Clin Med; 2000 Oct; 136(4):320-7. PubMed ID: 11039853
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased circulating levels of soluble Fas ligand are correlated with disease activity in patients with fibrosing lung diseases.
    Kuwano K; Maeyama T; Inoshima I; Ninomiya K; Hagimoto N; Yoshimi M; Fujita M; Nakamura N; Shirakawa K; Hara N
    Respirology; 2002 Mar; 7(1):15-21. PubMed ID: 11896896
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnostic significance of serum concentrations of soluble Fas ligand (sFasL) in children with autoimmune thyroid disease.
    Mikos H; Mikos M; Niedziela M
    Autoimmunity; 2017 May; 50(3):192-198. PubMed ID: 28276714
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential regulation of Fas-mediated apoptosis in both thyrocyte and lymphocyte cellular compartments correlates with opposite phenotypic manifestations of autoimmune thyroid disease.
    Giordano C; Richiusa P; Bagnasco M; Pizzolanti G; Di Blasi F; Sbriglia MS; Mattina A; Pesce G; Montagna P; Capone F; Misiano G; Scorsone A; Pugliese A; Galluzzo A
    Thyroid; 2001 Mar; 11(3):233-44. PubMed ID: 11327614
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Physical training modulates proinflammatory cytokines and the soluble Fas/soluble Fas ligand system in patients with chronic heart failure.
    Adamopoulos S; Parissis J; Karatzas D; Kroupis C; Georgiadis M; Karavolias G; Paraskevaidis J; Koniavitou K; Coats AJ; Kremastinos DT
    J Am Coll Cardiol; 2002 Feb; 39(4):653-63. PubMed ID: 11849865
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modulation of Fas-mediated apoptosis of human thyroid epithelial cells by IgG from patients with Graves' disease (GD) and idiopathic myxoedema.
    Kawakami A; Eguchi K; Matsuoka N; Tsuboi M; Urayama S; Kawabe Y; Tahara K; Ishikawa N; Ito K; Nagataki S
    Clin Exp Immunol; 1997 Dec; 110(3):434-9. PubMed ID: 9409648
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulation of apoptosis in endocrine autoimmunity: insights from Hashimoto's thyroiditis and Graves' disease.
    Salmaso C; Bagnasco M; Pesce G; Montagna P; Brizzolara R; Altrinetti V; Richiusa P; Galluzzo A; Giordano C
    Ann N Y Acad Sci; 2002 Jun; 966():496-501. PubMed ID: 12114310
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum CD40/CD40L system in Graves' disease and Hashimoto's thyroiditis related to soluble Fas, FasL and humoral markers of autoimmune response.
    Mysliwiec J; Oklota M; Nikolajuk A; Waligorski D; Gorska M
    Immunol Invest; 2007; 36(3):247-57. PubMed ID: 17558708
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thyroid hypoechogenicity after methimazole withdrawal in Graves' disease: a useful index for predicting recurrence?
    Zingrillo M; D'Aloiso L; Ghiggi MR; Di Cerbo A; Chiodini I; Torlontano M; Liuzzi A
    Clin Endocrinol (Oxf); 1996 Aug; 45(2):201-6. PubMed ID: 8881453
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.